

GGAGTCAC-3'" insert -- (SEQ ID NO. 84) --.

On page 62, line 24, after "CAGACCACCACCGGATCCGTAAAGCTGCCAGG

ATGAACTCTAG-3'" insert -- (SEQ ID NO. 85) --.

On page 62, line 28, delete "*et al.*" and substitute -- et al. -- therefor.

On page 64, line 11, delete "POROS" and substitute -- POROSTM -- therefor.

On page 67, line 17, delete "*et al*" and substitute -- et al. -- therefor.

In the Claims:

Please cancel the originally filed claims 1-21, without prejudice to further prosecution in a related application, and add the following new claims:

22. (New) A recombinant soluble T cell receptor (TCR) which comprises:

- i) a TCR α or γ chain extracellular domain having a first C-terminal dimerisation peptide which is heterologous to the α or γ chain; and
- ii) a TCR β or δ chain extracellular domain having a second C-terminal dimerisation peptide which is heterologous to the β or δ chain;

wherein the first dimerisation domain and the second dimerisation domain are specifically heterodimerised to form a heterodimerisation domain; and

wherein a disulphide bond present in native TCRs between the α and β or γ and δ chain is absent.

23. (New) A recombinant TCR according to claim 22 wherein said TCR is stable at low concentrations.

24. (New) A recombinant TCR according to claim 22 wherein said TCR is stable at a concentration of about 20 mg/ml.

25. (New) A recombinant TCR according to claim 22 wherein said TCR is stable at a concentration below 1 mg/ml.

26. (New) A recombinant TCR according to claim 22 wherein said TCR is stable at a concentration of about 10 µg/ml.

27. (New) The recombinant TCR according to claim 22, wherein the heterodimerisation domain is a coiled coil domain.

28. (New) The recombinant TCR according to claim 27, wherein the dimerisation peptides are c-jun and c-fos dimerisation peptides.

29. (New) The recombinant TCR according to claim 22, comprising a flexible linker located between the TCR chains and the dimerisation peptides.

30. (New) The recombinant TCR according to claim 22, expressed in an *E. coli* expression system.

31. (New) The recombinant TCR according to claim 22, which is biotinylated at the C-terminus.

32. (New) The recombinant TCR according to claim 22, labeled with a detectable label.

33. (New) The recombinant TCR according to claim 22, linked to a therapeutic agent.

34. (New) A recombinant non-membrane-bound T cell receptor produced by:

- i) expressing a TCR α or γ chain extracellular domain having a first C-terminal dimerisation peptide which is heterologous to the α or γ chain;
- ii) expressing a TCR β or δ chain extracellular domain having a second C-terminal dimerisation peptide which is heterologous to the α or γ chain; and